

Supplemental Approvals

Generic Name (Trade Name—Company)

September 26, 2018

Latanoprost ophthalmic emulsion 0.005%

(Xelpros—Sun Pharma)

Topical formulation reduces IOP in open-angle glaucoma or ocular hypertension

Uses/Notes

Sun Pharma [announced](#) FDA approval of latanoprost ophthalmic emulsion 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

It is the first and only form of latanoprost that is not formulated with benzalkonium chloride, a preservative commonly used in topical ocular preparations.

Recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. Reduction of IOP starts approximately 3 to 4 hours after administration, and the maximum effect is reached after 8 to 12 hours.

In clinical trials, the most frequently reported adverse reactions were eye pain/stinging upon instillation and ocular hyperemia (redness).

Source URL:

<http://aphaduginfoline.com/supplemental-approvals/topical-formulation-reduces-iop-open-angle-glaucoma-or-ocular-hypertension>

A_{PhA} DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in A_{PhA} DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of A_{PhA}. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in A_{PhA} DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.